Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07264634 · ClinicalTrials.gov registry record
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
A clinical trial, sponsored by Ascendis Pharma A/S.
- Recruiting
- Registry status
- 10
- Enrollment target
NCT07264634 is a clinical trial that is actively recruiting participants, run by Ascendis Pharma A/S. The registered enrollment target is 10 participants.
The verdict
NCT07264634 is actively recruiting participants, sponsored by Ascendis Pharma A/S.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.
Interventions
- DRUG Palopegteriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2028-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07264634
The ClinicalTrials.gov registry entry for NCT07264634 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma A/S, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Palopegteriparatide is the first listed.
NCT07264634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07264634 about?
NCT07264634 is a clinical study titled "A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)". This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast...
What is the current status of trial NCT07264634?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2026-03-19. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07264634?
The interventions under investigation include: Palopegteriparatide (DRUG).
Who is sponsoring clinical trial NCT07264634?
This trial is sponsored by Ascendis Pharma A/S, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.